Our oncology therapies are specifically designed to overcome treatment-resistant cancer mutations. Theseus Pharmaceuticals is passionately committed to outsmarting cancer resistance. Cancer is constantly mutating, allowing it to evade initially effective oncology treatments. Theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance.

Led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (TKIs), we are developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology. As tumor mutations arise during treatment, current-generation TKIs become ineffective. With predictive assays and a pan-variant strategy, Theseus can anticipate why treatments fail. Empowered by this knowledge, we aim to design TKIs that target known mutations, and prevent the emergence of new ones.